Table 2.
Outcomes in HIV-positive patients undergoing alloHCT for malignant and non-malignant hematological disorders
| Outcomes | N eval | N |
|---|---|---|
| Median days to neutrophil engraftment, (range) | 18 | 16 (7–30) |
| Cumulative incidence of Grade II-IV acute GVHD, Prob. (95% C.I.) | 23 | |
| @ 100 days | 30 (14–50)% | |
| Cumulative incidence of chronic GVHD, Prob. (95% C.I.) | 23 | |
| @ 1 year | 28 (12–48)% | |
| @ 2 years | 28 (12–48)% | |
| Episodes of infection post HCT | ||
| ≤100 days | ||
| Culture positive bacterial | 10 | |
| Invasive fungal | 1 | |
| PCP | 0 | |
| CMV reactivation | 3 | |
| Mycobacteria | 0 | |
| Hepatitis B or C | 1 | |
| Others | 5 | |
| >100 days | ||
| Culture positive bacterial | 4 | |
| Invasive fungal | 1 | |
| PCP | 0 | |
| CMV reactivation | 0 | |
| Mycobacteria | 0 | |
| Hepatitis B or C | 1 | |
| Others | 2 | |
| Median follow-up of survivors, (range), months | 6 | |
| Prior to 1996 (n=2) | 75 (59–90) | |
| After 1996 (n=4) | 51 (23–74) | |
| Overall survival, Prob. (95% C.I.) | 23 | |
| @ 1-y ear | 30 (14–50)% | |
| @ 2-years | 30 (14–50)% | |
| Primary causes of death | 17 | |
| Disease relapse | 1 (6%) | |
| NRM | ||
| Regimen-related toxicities | ||
| Pulmonary toxicity | 6 (35%) | |
| Other organ toxicities | 3 (19%) | |
| Graft failure | 1 (6%) | |
| Infections | 4 (24%) | |
| GVHD | 1 (6%) | |
| Others | 1 (6%) | |
GVHD, graft-versus-host disease; PCP, pnemocystis carinii pneumonia; CMV, cytomegalovirus; NRM, non-relapse mortality